Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2001
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Key products include EPOGEN (Epoetin alfa) and NEUPOGEN (Filgrastim). The company recently received U.S. approval for Aranesp (darbepoetin alfa) for anemia treatment, launching in October 2001.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2001 | Nine Months Ended Sep 30, 2001 |
|---|---|---|
| Total Revenues | $1,003.1 | $2,891.4 |
| Net Income | $329.9 | $956.7 |
| Earnings Per Share (Diluted) | $0.30 | $0.88 |
| Operating Cash Flow (9 months) | $954.7 | |
| Cash & Marketable Securities | $2,429.2 (as of Sep 30, 2001) | |
| Long-Term Debt | $223.0 | |
| Commercial Paper Outstanding | $100.0 | |
| Cost of Sales Margin | 11.7% of Product Sales | 11.5% of Product Sales |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 6% year-over-year for the quarter ($1,003.1M vs. $949.5M) and 8% for the nine-month period ($2,891.4M vs. $2,678.0M). Product sales grew 3% in the quarter and 8% for the nine months.
- Net Income: Net income decreased 8% in the quarter ($329.9M vs. $358.9M) but increased 3% for the nine months ($956.7M vs. $927.7M). The prior year quarter included a one-time $73.9M legal award benefit not present in the current period.
- Operating Expenses: Research and development expenses rose 7% in the quarter and 6% for the nine months, driven by staff-related costs. Selling, general, and administrative (SG&A) expenses increased 9% and 12%, respectively, due to marketing and consulting costs.
- Cash Flow: Net cash provided by operating activities decreased to $954.7M for the nine months ended Sep 30, 2001, compared to $1,262.9M in the prior year period, largely due to changes in working capital (increases in receivables and inventory).
- Stock Repurchases: The company repurchased 8.4 million shares for $487.6M in the first nine months of 2001, compared to 9.9 million shares for $645.1M in the same period of 2000.
Guidance, Outlook, and Risks
- Product Outlook:
- EPOGEN/Aranesp: Management expects combined sales to grow at a low-double digit rate in 2001. Aranesp was launched in the U.S. in October 2001; sales growth will depend on the transition from EPOGEN.
- NEUPOGEN: Expected to grow at a high-single digit rate in 2001, subject to competitive pressures and reimbursement changes.
- Financial Guidance (2001):
- Total product sales and earnings per share (excluding non-recurring items) expected to grow at low-double digit rates.
- Corporate partner revenues expected to be lower than 2000 levels.
- Cost of sales estimated at 11% to 12% of total product sales.
- R&D and SG&A expenses estimated at 25% to 27% of total product sales each.
- Effective tax rate expected to be approximately 34%.
- Risks and Contingencies:
- Praecis Collaboration: The agreement to jointly develop Plenaxis was terminated in September 2001. Amgen has $60M in capitalized costs and believes a loss is reasonably possible, though the amount cannot be estimated.
- Legal Proceedings: Ongoing arbitrations with Johnson & Johnson (trial scheduled Jan 2002) and patent litigation with Genentech and Biogen.
- Reimbursement: Sales of EPOGEN and NEUPOGEN are sensitive to federal government reimbursement rates and private insurance policies.
Investor Verification Checklist
- Verify the impact of the Plenaxis collaboration termination on future earnings and the potential magnitude of the unaccrued loss.
- Monitor the adoption rate of Aranesp versus EPOGEN in the U.S. dialysis market following the October 2001 launch.
- Review the status of the Johnson & Johnson spillover arbitration scheduled for January 2002.
- Assess the effect of wholesaler inventory management on quarterly product sales volatility.
- Confirm the company's ability to maintain the projected 34% effective tax rate given the Puerto Rico tax provision cap.